The association of thrombophilia with pregnancy complications has received increasing attention. It is now apparent that thrombophilia is respernsihle for a large number of the serious complications of pregnancy such as venous thrombosis, pulmonary embolism, fetal loss, pregnancy loss, intrauterine fetal demise, and preeclampsia. The inherited thrombophilia abnormalities, factor V Leiden mutation, prothrombin gene mutation 20210A, and antithrombin III, protein C, and protein S deficiency, and the acquired disorders, the anticardiolipin syndrome and lupus inhibitor, are responsible for a large share of the incidences of premature termination of preg-
nancy and many of the above complications. The normal physiology of pregnancy may be prothrombotic, with evidence for increased markers of activated coagulation and coagulation factors. There is a decrease in protein S and resistance to activated protein C occurs in a significant number of pregnancies in the absence of the factor V Leiden mutation. In the following article, we review some of the major studies that have correlated the thrombophilia and other acquired disorders that adversely impact pregnancies. Key Words: Coagulation activation mark-ers&mdash;Endogenous thrombin potential&mdash;APCR&mdash;Thrombinactivatable fibrinolysis inhibiter.
Normal pregnancy is associated with changes in the coagulation system that might contribute to a hypercoagulable or prothrombotic state. In pregnancy, there are reported increases in the levels of coagulation factors and decreases in the natural anticoagulants (1, 2) . In addition, there are several other documented manifestations of hypercoagulability in pregnancy, such as the development of resistance to activated protein C (APCR), which occurs in up to 60% of pregnancies (3) (4) (5) . Pregnant women have a risk of venous thromboembolism (VTE) that is five times as high when compared with similarly agematched nonpregnant women (6--8) . Venous thromboembolism is the leading cause of morbidity and mortality in pregnancy and the puerpcrium (9, I~) . The incidence of pregnancy-associated VTE is estimated to be from 1 in 1,000 to I in 2,000-,deliveries 11,1 ~~. The markers of activated coagulation, which reflect the increase in the generation of thrombin, have been shown to increase during pregnancy i 3; ~ 6~-1 ~~.
The evaluation of coagulation activation and thrombin potential in healthy pregnancies in women with and without factor V Leiden (FVL) was reported by Eichinger et al. (13) . In this study, the authors assessed 113 pregnant women: I 1 v~ith FVL and 102 without FVL.
They measured prothrombin fragment 1.2 (PFI.2), thrombin-antithrombin complex (TAT), D-dimer (DD), and endogenous thrombin potential (ETP) at the 12th, 22nd, and 34th week of gestation, and at 3 months after delivery, which was considered the baseline in each subject. None of the women developed VTE during the period of observation. Both groups developed increased levels of PFI.2, TAT, and DD throughout uncomplicated pregnancy, with levels similar to those seen in acute thromboembolic events (~ ~ 0.0001). The DD levels were significantly higher in the FVL patients ~ = 0.0005). The ETP remained unchanged in both groups at all time points. The authors concluded that there was no difference in the activation markers in the FVL-positive and -negative women, activation markers are increased in pregnancy. In this study, was no relationship to thrombosis. The finding of normal ETP in pregnancy suggests that the capacity to generate thrombin does not change in pregnancy. The increased DD in women with FVL at baseline and during pregnancy indicates an increased activation of the fibrinolytic system in carriers of the FVL mutation. Overall, this data is at variance with several other studies, which indicate that patients with abnormalities associated with thrombophilia have greater increases in coagulation activation markers. Possibly, the subjects in this study were less reflective because they had no patients with thrombotic events. In our laboratory, we have demonstrated, using the ETP assay system, that there is a development of a degree of resistance to activated protein C in normal pregnancies (unpublished data) ( Fig. 1 ; A through D). When pregnant women in the first through third trimesters were compared with a normal population, male and female, the ETP revealed no significant rise in thrombin potential. However, when the ETP was a;sessed after treatment of the plasma samples with activated protein C (APC), a clear demonstration of APC resistance was evident in the second and third trimesters. In the same group of healthy pregnant women, we noted a significant rise in coagulation activation markers, PFl.2, TAT, and TpP in the second and third trimesters (Fig. 2 ). In this same group, the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) increased significantly in the second and third trimesters (Fig. 3 ). These findings suggest that in normal pregnancy there are changes that indicate increased thrombin activity and a decreased ability to down-regulate thrombin production. The increase in TAFI would imply that there may be some resistance to fibrinolysis. Nowak-Gottl et al. (14) reported increased levels of DD in heterozygous FVL children and the au-thors, in unpublished data, found that heterozygous adults with history of ~ITE I~~d higher DD than patients without FVL. Pregnant women with FVL have higher incidence and risk of VTE than those without the mutation (15) . Carriership for the FVL mutation is associated with increased risk for venous thrombosis. Some heterozygotes for FVL have increased PFI.2 and TAT levels, but normal levels are noted in the majority flf both symptomatic and asymptomatic carriers (Ifi-l9). The physi-ology of pregnancy creates a prothrombotic milieu, and it is not surprising that much of the data suggests that pregnancies in women with thrombophilia abnormalities are at significantly higher risk for thrombosis and fetal loss (3, (20) (21) (22) (23) (24) (25) (26) (Tables I and 2 ).
Thrombophilia is the tendency to idiopathic, easily provoked, early-onset, or recurrent thrombosis related to inherited or acquired abnormalities in the coagulation system (Tables 3 and 4 ). The inherited abnormalitiesantithrombin III deficiency (ATIII D) and protein C (PCD) and protein S (PSD) deficiencies-have been as-;sociated with thrombosis in pregnancy and the puerperium (Tables 5 and 6 ). It has become increasingly evident that thrombophilia is associated with pregnancy and fetal loss. Protein S is routinely reduced during pregnancy, and an inherited deficiency creates a greater risk for thrombosis, particularly during the postpartum period (27) . In absolute numbers, the data suggest that APCR occurs in up to 60% of first episodes of thrombosis in pregnancy (28). For the most part, APCR associated with thrombosis is due to the FVL mutation in the factor V gene. Other causes of APCR have been demonstrated.
The high incidence of APCR, which cannot solely be explained by the FVL mutation, may be related to other factor V polymorphisms, physiologic changes in pregnancy, the anticardiolipin syndrome, and other factors (29,30). As noted above, the frequent development of APCR in pregnancy has been widely described (23, 31) .
APCR may be due to the increased levels of factor VIII, the decrease in the levels of free protein S, or both. The sensitivity for the detection of APCR may be related to the use of a less specific variety of tests. It is not unreasonable to postulate a physiologic mechanism for the development of resistance to APC during pregnancy, possibly to decrease bleeding at delivery. Deguchi et al. (32) reported the deficiency of plasma glucosylceramide (GlcCer) as a potential risk factor for venous thrombosis. It is a modulator of the anticoagulant protein C pathway. Pregnancy and oral contraceptive use may reduce GIcCer synthase, the enzyme that synthesizes GlcCer. Estradiol has been reported tao have this effect, and it also raises j glucosidase activity (33). This suggests that plasma . GlcCer levels might be reduced by pregnancy or oral I contraceptive use. Therefore, there may be multiple path-: ways to help explain the many reports of increased inci-! dence of pregnancy loss, fetal loss, and venous throml bosis in women with the FVL mutation and non-FVLrelated APCR (20, 22) . PREGNANCY L~D~'~' AND THROMBOPHILIA Grandone et al. (34) noted that the FVL' mutation is associated with repeated and recurrent unexplained fetal losses. They looked at 43 patients, all Caucasians, with a ' history of two or more unexplained fetal losses, One hundred eighteen women served as a control group. In the initial case group of 19 women, 2 had fetal losses, 12 had three fetal losses, 8 had four losses, and 4 had four or more fetal losses. The prevalence of the FVL mutation in the women with two fetal losses, 15.8%, was not different from those with recurrent losses, 16%. However, there was a significantly higher rate of FVL in those with losses during the second and third trimester, 16.3%, versus ~.2%a of controls (p = t~.Q11}. In addition, there was a significant increase in the later trimester fetal losses as compared with those in the early trimester period (p = 0.04).
Mello et al. (35) studied 34 consecutive women with a history of fetal loss in the second and third trimester and 46 consecutive women with history of preeclampsia (Table 7) . Their observations reveal that there is a relationship between FVL and fetal loss and preeclampsia. Increased occurrence of fetal loss in the patients with the lupus anticoagulant (LAC) is also evident. The combination of the lupus inhibitor (LAC) or anticardiolipin antibodies (ACA) with FVL increased the incidence of preeclampsia. An increase in preeclampsia in patients with PSD and PCD has also been noted. The combination of disorders increased the risk for pregnancy complications.
Ridker et al. (36) noted that the FVL mutation was greater among case-patients (8.0%) with pregnancy loss than among control subjects (3.7%) (p = 0.05). In the cases with three or more pregnancy losses and no successful pregnancies, the prevalence of this mutation was 9.0% (p = 0.048). In all patients with several pregnancy losses, the prevalence of FVL was 2.2-fold greater than in control subjects (p = 0.026). Unexplained recurrent fetal loss in nonthrombotic, nonimmune women with the antiphospholipid syndromes was examined by the Nimes Obstetricians and Hematologists Study (37) . They previously had shown that ACA IgG or a positive anti-P2-glycoprotein I (anti-02-GPI) IgG is an independent risk factor for late fetal loss (still birth) in nonthrombotic women. They looked at early fetal loss in nonthrombotic women, using conventional phospholipid-dependent assays (LAC: IgM and IgG anticardiolipins antibodies [IgM-ACA Ab, IgG ACA 'Ab~)~' r~c~ncc.>n~en~ic~n~I phospholipid-containing assays (anti-phosphatidylethanolamine [aPEAb], IgM or IgG antibodies fIgM-aPE Ab; !gG-aPE Ab]) and phospholipid-free assays (anti-P2 GPI IgM or Ig~'r: anti-annexin V IgM or IgG; anti-prothrombin IgG or IgM. Women, aged 18 to 45 years, who had at least three episodes of unexplained early fetal loss from the 8th week to the 2'~nd week of gestation were studied. They had no other known cause, such as thmmbophilia, other autoimmune disease, inflammatory disease, human immunodeficiency virus (HIV), or lymphoproliferative disease. The above assays gave significantly greater values as compared with control subjects and increased with the number of pregnancies. Positive LAC, anti-02-GPI IgG, antiannexin V IgG, anti-prothrombin IgG or antiPE IgM were more frequent in patients with unexplained fetal loss than those with explained fetal loss. The levels of ' inti~ardis~Iipin antibody reactivity were generally weak.
The number of positive tests was not related to the number of pregnancies in explained and unexplained fetal loss. When testing for LAC, two thirds were positive in only one test, and low levels of positivity was the rule. About 50% had low positive DR~VT. Brenner et al. (38) reported on thrombophilic poly-' morphisms (TP) in fetal loss. They noted that others have reported recurrent fetal loss of three or more affects I to 2% and two or more in up to 5% of women of reproductive age (38, 39) . In their study, the authors looked at FVL, prothrombin gene mutation ~()?~~A (PGM), and MTHFR C677T. Their data are demonstrated Tables 8  and 9 . '
Observations from data in '?~ consecutive women with fetal loss There is a correlation of FVL with fetal loss. Thrombophilia pt~lymarphisms (TP) were correlated with fetal loss. Independently, the PGM and homozygosity for the MTHFR mutation C677T were not significantly related to fetal loss. The patients with TP had a lesser rate of fetal loss in the first trimester. This may be related to less risk for bleeding. The incidence of second trimester miscarriage was significantly increased in patients with TP. Intrauterine fetal demise was also significantly greater in patients with TP. ; Overall, the data sta~gest that'~'Ps increase the risk for ! premature pregnancy termination and fetal loss in the i latter stages of pregnancy and increase the risk for intrauterine fetal death. The patients with the FVL mutation had a significantly greater risk for fetal loss in the second and third trimester. These data support the evidence that carriers of FVL have a significant risk of late miscarriage or stillbirth. The authors suggested that in women with FVL, consideration for thromboprophylactic measures must be given after the first trimester of pregnancy. Murphy et al. (41) assessed the prospective evaluation of 584 screened pa-, tients for risk conferred by FVL and MTHFR mutation in pregnancy. They found that FVL was a significant factor in miscarriage after the first trimester. However, the : MTHFR and FVL mutations did not reach signifi-. cance in recurrent fetal loss. It was also noted that in TABLE 6. Major thrombophilia defects in pregnancy ! ARC. activated protein C; ATUL antithrombin 111; Lp(a), fipgpa%ek (a). Adapted from Mello et al. (35) . APCR, activated protein C resistance; FVL, factor V Leiden; PCD, protein C deficiency; PSD, protein S deficiency; LAC, lupus anticoagulant; ACA. anticardiolipin antibody. patients with prior venous thrombosis FVL was significantly increased.
Lindqvist et al. (42) examined the finding off APCR and FVL and pregnancy in a prospective study of 2,480 pregnant women. The outcomes of VTE, intrapartum blood loss, and the prevalence of selected pregnancy complications such as fetal loss, preeclampsia, and intrauterine growth retardation, were assessed. They found that the prevalence of APCR was I I% in 270 of 2,480 patients. The APCR group did not differ from the non-APCR group in terms of pregnancy complications. However, there was an eightfold higher risk of VTE and a lower rate of profuse intrapartum hemorrhage (p = 0.02). They used the modified Coatest with factor V-dcpleted plasma to detect APCR. This may have influenced the detection of causes of APCR other than FVL. The data from this study differ from the majority looking at fetal loss and premature terminations of pregnancies. However, the greater incidence of venous thrombosis is consistent with other reports, as noted below.
Martinelli et ah (43) reported a study investigating FVL, PGM, and the mutation for the MTHFR enzyme in women with fetal loss at 20 weeks of pregnancy or later.
In their data, 16% of 67 patients with fetal loss and 6% ' of 232 controls had either FVL or PGM. The relative risks of late fetal loss in the carriers of FVL and the PGM were 3.2 (1.0 to 10.9) and 3.3 (1.1 to 10.3), respectively, There was no statistical evidence for a risk to the MTHFR mutation. In this study, the patients with other (44) noted the detection of deep vein thrombosis in obstetric patients by the diagnostic use of impedence plethysmography in patients suspected of venouns thrombosis during pregnancy. In 77 patients with symptoms of deep vein thrombosis (DVT), 42% had an abnormal IPG. Those with repeated normal IPG did not develop DVT. However, 26% of the patients with a positive IPG and DVT were positive for a coagulation of f brinc~lyti~ abnormality. They suggested that serial IPGs could be used effectively in obstetric patients with ~clinically suspected DVT and in those with hemostatic abnormalities that may increase the frequency of DVT. More sensitive and specific zaar~in~~aiue testing methods are needed for the pregnant population. A 60% incidence of APCR was noted women with previous VTE related to pregnancy (45) . The same study noted that in 30% of women with VTE using oral contraceptives had APCR. The incidence of APCR is high in this study, but reflects the use of a less specific assay, and a cutoff level of the APCR ratio of 2.0. However, an increased degree of APCR is well documented in pregnancy and with OC and is not dependent on FVL.
The association of VTE and FVL in the early phases of pregnancy was noted by Hirsch et al. (22) . In their study, first-trimester pulmonary embolism or DVT developed in 6 of 10 women with the mutation compared with 3 of 40 without the mutation (1,) = 0.0009). Overall, their data indicate that FVL was a risk factor for VTE during pregnancy and after delivery. They noted that the early onset of VTE would have an impact on the considerations for the timing of thromboprophylaxis.
The risk factors for VTE associated with pregnancy were assessed by McCc~ll et al. (46) . In a retrospective analysis of 72,000 deliveries, they found 51 with DVT and 1 l with pulmonary embolism, with an incidence of 0.71 per 1,000 deliveries for DVT. There was an incidence of 0.50 per 1,000 in the antenatal period and 0.21 1 per 1,000 in the puerperium. The incidence of pulmonary embolism was £~.IS per 1,000 deliveries, with 0.07 antenatal and 0.08 in the puerperium. Fifty of the 62 cases with VTE were followed up for thrombophilia screening, with the finding o antithrombin III (ATIII) deficiency in 12% and FVL in 8% (PGM not performed). Based on the prevalence of FVL in the population, they estimated that the thrombotic risk for FVL in pregnancy or the puerperium is 1 in 400 to 5~1f)* The risk estimated for ATIII deficiency is I in 2.8 for typo 1, 1 in 42 for type II, and 1 in 113 for protein C deficiency. This suggests that FVL is a weaker prothrombotic problem, and is less provocative than the deficiencies of the natural inhibitors of coagulation, such as ATIII and PCD.
The same group of investigators, in a retrospective study of 72,000 deliveries, examined the occurrence of superficial vein thrombosis (SVT) associated with pregnancy and the relationship to thrombophilic defects (47) . Forty-nine cases of SVT were diagnosed in 47 patients, with an incidence of 0.68 per 1,000 deliveries. Most events occurred in the early postpartum period. Twentyfour of 47 patients were screened for thrombophilia, and ' only one patient was found to have FVL. They concluded that SVT is not associated with the thrombophilia conditions in pregnancy. The patients were not tested for PGM, but were tested for ATIII, PC, PS, APCR, LI, and ACL.
Gerhardt et al. (48) studied the relation of PGM 20210A, FVL, ATII deficiency, PCD, and PSD in women with thrombosis during pregnancy and the puerperium. One hundred nineteen consecutive women with a history of VTE during pregnancy and the puerperium ( up to 6 weeks postpartum) and 233 normal women were studied (Table 10 ). Ã logistic regression analysis with adjustments far i age, body mass, and oral contraceptive use or nonususe & d q u o ; was made, and only ATIII deficiency «80% level), I FVL, and PGM were identified as independent risk factors that were predictive of thrombosis in the women ) with VTE. j Their data suggest that ATIII deficiency had a trend 1 toward increased VTE in the postpartum period and / / MTHFR mutation was predominantly a factor in the / pc~~tpartum period. However, there was no significant ) difference in prevalence of FVL, PGM, PCD, and PSD in ' ) the pregnancy and postpartum period. Recurrent VTE / was associated with PGM, ATIII deficiency, and PGD, ) and there was a higher incidence of combined defects ) with recurrence of thrombosis. A disproportionately , higher incidence of VTE was noted in the patients with I combined mutations.
)
Brill-Edwards et al. (49) addressed the safety of with-) holding heparin in pregnant women with a history of i VTE greater than 3 months before the current pregnancy. '
1 They studied 125 pregnancies, and in 2.4% an antepar-) tum recurrence of VTE occurred. There were no recurj rences in the 44 women with no evidence of thrombo-/ philia or with a temporary risk factor associated with the previous episode. In the 51 patients with thrombophilia or an idiopathic VTE, 5.9% had an antepartum recur-» rence. These data suggest that not all pregnant women / with a previous VTE need be treated with prophylactic ! anticoagulants. However, it also indicates that the pres-! ence of thrombophilia and previous idiopathic VTE are risk issues.
j The data from the listed studies suggest that abnor-' malities in the natural anticoagulation system induce varying degrees of increased risk for thrombosis in pregnancy and the puerperium. The possibility that other inherited defects, as yet undefined, may also play a role as risk factors is quite likely. The mutations for FVL and ! PGM are weaker risk factors for thrombosis, but the risk ! is compounded in patients with combined abnormalities.
! The other deficiencies of the natural inhibitors of coagu-! lation, such as ATIII deficiency > PC > PS, are with higher risk for thrombosis. The mutation for the gene for MTHFR seems to induce increased risk during the puerperium. Future studies may find other genetic markers i and polymorphisms in addition to functional abnormali-! ties related to the prothrombotic and fibrinolytic systems ! that play a major role in thrombosis related to pregnancy. ! THE ANTIPHOSPHOLIPW ANTIBODY ! SYNDROME AND PREGNANCY j The antiphospholipid antibody (APA) syndrome is a well-documented cause of pregnancy loss, fetal loss, and thrombosis (50) . We have noted in some of the abovej mentioned studies substantial data that support the independent and additive risk effects of the lupus inhibitor and anticardiolipin antibodies for complications in pregnancy and thrombosis. The difficulty is assessing the asymptomatic patient with positive tests for antiphospholipid antibodies for the risk of pregnancy loss or thrombosis. The substantial number of patients with positive tests who have no adverse clinical consequences magni-I fies this issue. There are many studies looking at differ-ent markers that would be informative in assessing patients with antiphospholipid antibodies.
Pregnancy is associated with markers of increased activation of coagulation, which might indicate a greater predisposition to thrombosis. Zangari et ~1. (S l ) reported on the increase in coagulation activation markers during pregnancy with the APA syndrome. They noted that affected pregnant women had higher levels of PFI.2 than unaffected normal pregnant women. Mello et al. (35) noted that the lupus inhibitor and antiphospholipid antibodies were independent and additive risk factors for pregnancy loss and preeclampsia. Therefore, it has become increasingly important to determine whether a pregnant patient has anticardiolipin antibodies or the lupus inhibitor, or both.
To this end, studies are in progress to look at associated antibodies and abnormalities that would increase the significance and meaning of the finding of the anticardiolipin antibodies in pregnancy. The issue of the significance of the presence of anti-J32-0PI and anti-prothrombin antibodies with thrombosis in pregnancy and pregnancy loss was examined by Forastiero et al. (52) . Using enzyme-linked immunsorbent assay, they studied 233 patients with LA or ACL, or both, for the anti-P2-GPI and anti-prothrombin antibodyies (anti-11) IgG and IgM.
Their findings were as follows: Forty-four women had history of pregnancy loss. Forty-five patients had history of venous thrombosis.
« Thirty-two had arterial thrombosis.
The patients in the autoimmune group (SLE, antiphospholipid syndrome) had a higher prevalence of anti (32-GPI. and or anti-11 antibodies or both than found in the miscellaneous group.
. There was a significant association shown between the presence of anti P2-GPI (odds ratio [OR] 3.2) and previous venous thrombosis but not arterial thrombosis.
. The presence of anti-11 antibodies was related to venous thrombosis.
. A multivatiate analysis showed that anti ~3~-~'a~I was the only independent risk for venous thrombosis (OR 3.0). ' The presence of anti P2-GPI-IgM correlated well with a history of pregnancy loss (OR 2.6). They concluded that the measurement of anti-02-GPI IgG and IgM could help to identify anticardiolipin antibody-positive patients with a higher risk for thrombosis and pregnancy loss.~~~~I l'~-~ AND THE ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY Rand eft al. (53) reported a possible thrombogenic mechanism in the antiphospholipid antibody syndrome and pregnancy loss. Annexin V, a phospholipid-binding protein with potent anticoagulant activity, is markedly reduced on placental villi in women with this syndrome.
APA antibodies lowered the levels of annexin V on cul-' ~ure~'trcaphobl~~t~ and human vein enc3oth~~i~l ~ells; The APA exposed cells showed accelerated coagulation effect. The authors postulated that the reduced annexin V in the APA syndrome is an important mechanism for thrombosis and pregnancy loss. In another study (54) , the APA IgG was found to reduce the levels of the syncytiotrophoblast apical membrane-associated annexin-V in placental villi and release of annexin-V into surrounding media. The reduction of this anticoagulant protein at the matemnal-fetal interface may account for the pregnancy loss in the APA syndrome. Donohoe et ;al. (55) investigated P2-glycoprotein-I and annexin V expression in normal villous tissues through pregnancy and in the antiphospholipid syndrome. Term placentas from APA patients had a reduced P2-GPI content, whereas there was ' increased annexin V/mg protein compared with normal placentas. Abnormal distribution of annexin V and (3' 2-GPI were noted in first-trimester APA placentas. The implications of abnormal Ic~cali~~tic>n of these proteins and the complications associated with the APA syn-' drome in pregnancy remain to be defined (Fig. 4 ).
F'REECI~~,~P~IA AND TOXEMIA He et al. (56) reported hemostatic, endothelial, and lipoprotein parameters and blood pressure levers in women with a history of p~ee~:Iamp~ia. They studied 25 women who had a history of preeclampsia. as compared with 24 controls. The patients had higher levels of von Willebrand factor, fibrinogen, cholesterol, triglycerides, and very-low-density lipoprotein (all p < 0.05). Only the von Willebrand factor increase was present in luteal and f~Ilic~Iar phase samples. The elevated von Willebrand factor levels suggest that the continued increase in factor VIII. may explain the higher risk for coronary heart disease in patients who have had precctampsia.
The association of the markers of fibrinolysis was examined by Proietti et al. (57) in patients with preeclampsia. They found that increased markers of lysis were noted in a statistical greater number of the preeclamptic women as compared with other pregnant and nonpregnant women. The markers of ~brinc~lysis could not differentiate the patients who developed HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome.
CONCLUSION
Increased prothrombotic markers and changes in the coagulation system are evident in pregnancy. This is based on the data showing an increase in the laboratory markers of activated coagulation, resistance to APC, decreased protein S, increased levels of several coagulation factors, and decreased fibrinolytic activity. Pregnant women with the inherited thrombophilia .abnormalities have significantly increased risks for venous thrombosis, ' pregnancy loss, and fetal loss. Women with FVL and PGM are associated, in the later two trimesters, with increased VTE and fetal loss. The pregnancy loss associated with the thrombophilia abnormalities tends to be in the latter two thirds of the pregnancy, whereas the complications related to the anticardiolipin antibodies may occur earlier in pregnancy. The thrombcaphili~z abnormalities are associated with an increased incidence of preeclampsia. The mutation associated with MTHFR may increase the risk for postpartum thrombosis. The anticardiolipins syndrome is associated with thrombotic complications and fetal loss. The combination of the anticardiolipin or lupus inhibitor with inherited thrombophilia increases the risk for preectampsia. The presence of ant'-P2-GPI antibodies may be more informative than anticardiolipin antibodies for thrombotic and other pregnancy complication risks, The anti-P2-GPI IgM antibodies may be more indicative for the risk for pregnancy loss, The evaluation for the at-risk pregnancy is in a constant state of change and review. However, at this time it seems appropriate to study the patient with history of recurrent loss. If there is a history of pregnancy complications in the family or a thrombotic history in the patient or the family, an evaluation before pregnancy or early in the pregnancy is indicated. ' * The evaluation for pregnancy loss in the second to or family history of early onset of vascular disease.) * The above evaluation is indicated in the pregnant women with history of idiopathic VTE or VTE with previous pregnancy or oral contraceptive use. The evaluation for early pregnancy loss should be directed to the anticardiolipin syndrome. The testing should include APA antibodies, ant'-P2-GPI antibodies, and lupus inhibitor testing with at least two different test systems to exclude the LI. The investigational tests, as mentioned above, are informative and can have predictive value. pregnancy in congenital deficiencies in ATIII. protein S/C: study of 78 women [letter). Thromb Haemost 1990;63:319. 
